Search Results

Zevra Therapeutics, Inc. today announced the completion of its acquisition of Acer Therapeutics Inc.

RELIEF THERAPEUTICS Holding SA (SWX:RLF), (OTCQB:RLFTF, RLFTY) (Relief Therapeutics) today announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. (Acer Therapeutics) for the development and commercialization of OLPRUVA™ (sodium phenylbutyrate, ACER-001) for the treatment of certain urea cycle disorders (UCDs) and other potential indications.

Zevra Therapeutics, Inc. and Acer Therapeutics Inc. announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million.

Acer Therapeutics Inc. reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Acer Therapeutics Inc. (Nasdaq: ACER) today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe).

Acer Therapeutics Inc. (Nasdaq: ACER) today announced an update on progress in support of its commercial launch of OLPRUVA™ (sodium phenylbutyrate) for oral suspension, including drug availability now expected earlier than anticipated in mid-June 2023, subject to additional capital.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Acer Therapeutics Inc. today announced the initiation of two Phase 2, single-arm investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate.

Acer Therapeutics Inc. (Nasdaq: ACER) today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant).

Acer Therapeutics Inc. (Nasdaq: ACER) today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company’s recent corporate developments.